Crinetics Pharmaceuticals, Inc. (CRNX) financial statements (2021 and earlier)

Company profile

Business Address 10222 BARNES CANYON ROAD, BLDG. #2
SAN DIEGO, CA 92121
State of Incorp. DE
Fiscal Year End December 31
SIC 2834 - Pharmaceutical Preparations (benchmarking)
More info Complete financial analysis Financial benchmarking

Balance sheet (Statement of financial position) ($ in millions)

12/31/2020
12/31/2019
12/31/2018
ASSETS
Current Assets
Cash, cash equivalents, and short-term investments, including:171118164
Cash and cash equivalents934045
Short-term investments7878119
Other undisclosed cash, cash equivalents, and short-term investments000
Receivables001
Prepaid expense1  
Other current assets111
Other undisclosed current assets531
Total current assets:177123167
Noncurrent Assets
Operating lease, right-of-use asset23
Property, plant and equipment344
Restricted cash and investments111
Other noncurrent assets00 
Total noncurrent assets:675
TOTAL ASSETS:183130171
LIABILITIES AND EQUITY
Liabilities
Current Liabilities
Accounts payable and accrued liabilities, including:658
Accounts payable  1
Accrued liabilities  4
Employee-related liabilities  2
Other undisclosed accounts payable and accrued liabilities65 
Debt 1 
Other liabilities11 
Other undisclosed current liabilities41 
Total current liabilities:1088
Noncurrent Liabilities
Long-term debt and lease obligation45 
Operating lease, liability45
Liabilities, other than long-term debt003
Deferred compensation liability, classified000
Deferred rent credit  3
Total noncurrent liabilities:453
Total liabilities:151311
Stockholders' equity
Stockholders' equity attributable to parent, including:169117160
Common stock  0
Additional paid in capital  204
Accumulated other comprehensive income000
Accumulated deficit(168)(94)(43)
Other undisclosed stockholders' equity attributable to parent337211 
Total stockholders' equity:169117160
TOTAL LIABILITIES AND EQUITY:183130171

Income statement (P&L) ($ in millions)

12/31/2020
12/31/2019
12/31/2018
Gross profit:012
Operating expenses(75)(55)(31)
Operating loss:(75)(54)(29)
Nonoperating income132
Investment income, nonoperating132
Net loss available to common stockholders, diluted:(74)(50)(27)

Comprehensive Income ($ in millions)

12/31/2020
12/31/2019
12/31/2018
Net loss:(74)(50)(27)
Other comprehensive income (loss)(0)00
Comprehensive loss, net of tax, attributable to parent:(74)(50)(27)

Statements sources

The financial statements are based on the company's filings with the The U.S. Securities and Exchange Commission (SEC) through the Electronic Data Gathering, Analysis, and Retrieval system (EDGAR). The information is derived from the 10-K and 10-Q reports submitted to the SEC in XBRL (eXtensible Business Reporting Language) format and presented according to the US GAAP Taxonomy. Please review the original filings for a more detailed information.

Login to ReadyRatios

 

Have you forgotten your password?

Are you a new user?

Login As
You can log in if you are registered at one of these services: